Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Eyepoint Pharmaceuticals Inc

Healthcare US EYPT

12.08USD
-0.95(7.29%)

Last update at 2026-06-15T20:00:00Z

Day Range

11.9313.33
LowHigh

52 Week Range

5.3019.11
LowHigh

Fundamentals

  • Previous Close 13.03
  • Market Cap1177.22M
  • Volume1081526
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-241.12499M
  • Revenue TTM31.37M
  • Revenue Per Share TTM0.43
  • Gross Profit TTM -187.74000M
  • Diluted EPS TTM-3.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -231.68300M -130.78000M -70.71200M -102.25400M -58.41700M
Minority interest - - - - -
Net income -231.96200M -130.87000M -70.79500M -124.51200M -63.91500M
Selling general administrative 51.61M 52.36M 40.10M 34.82M 25.57M
Selling and marketing expenses 0.09M 0.13M 11.69M 25.51M 27.50M
Gross profit 29.30M 39.56M 41.39M 33.08M 28.76M
Reconciled depreciation 2.31M 1.54M 0.46M 2.45M 2.77M
Ebit - -130.76600M -73.66200M -78.93800M -55.27600M
Ebitda -243.43400M -129.22600M -73.19800M -74.75700M -52.52400M
Depreciation and amortization - 1.54M 0.46M 4.18M 2.75M
Non operating income net other - - - 0.57M 2.36M
Operating income -243.43400M -145.85400M -73.66200M -78.93800M -55.27600M
Other operating expenses 274.81M 189.13M 119.68M 120.34M 92.22M
Interest expense 0.03M 0.01M 1.25M 3.19M 5.50M
Tax provision 0.28M 0.09M 0.08M 0.00000M -
Interest income 11.78M 15.09M 6.95M 2.13M 0.29M
Net interest income 11.75M 15.07M 5.70M -1.05800M -5.20600M
Extraordinary items - - - - -
Non recurring - - - 20.70M -
Other items - - - - -
Income tax expense 0.28M 0.09M 0.08M 22.26M 5.50M
Total revenue 31.37M 43.27M 46.02M 41.40M 36.94M
Total operating expenses 272.74M 185.41M 115.05M 112.02M 84.04M
Cost of revenue 2.07M 3.71M 4.63M 8.33M 8.18M
Total other income expense net 11.75M 15.07M 2.95M -23.31600M -3.14100M
Discontinued operations - - - - -
Net income from continuing ops -231.96200M -130.87000M -70.79500M -102.25400M -58.41700M
Net income applicable to common shares - - - -102.25400M -58.41700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 364.00M 418.46M 355.18M 180.36M 263.37M
Intangible assets - - - - 22.75M
Earning assets - - - - -
Other current assets 20.11M 9.48M 9.04M 9.86M 4.22M
Total liab 57.88M 81.96M 88.86M 83.99M 78.99M
Total stockholder equity 306.11M 336.50M 266.32M 96.37M 184.38M
Deferred long term liab - - - 13.56M 14.56M
Other current liab 2.14M 19.54M 17.60M 16.94M 14.42M
Common stock 1410.13M 0.07M 0.05M 766.93M 752.64M
Capital stock 0.08M 0.07M 0.05M 0.03M 0.03M
Retained earnings -1104.97800M -873.01600M -742.14600M -671.35100M -569.09700M
Other liab - - - 14.16M 16.91M
Good will - - - - -
Other assets - - - 0.15M 0.63M
Cash 101.82M 99.70M 281.26M 95.63M 178.59M
Cash and equivalents - - - - -
Total current liabilities 37.02M 49.05M 63.26M 34.54M 23.66M
Current deferred revenue - 17.78M 38.59M 1.21M 1.07M
Net debt -81.04900M -77.84600M -275.79400M -49.86400M -140.17100M
Short term debt - 1.25M 0.56M 10.47M 0.78M
Short long term debt - - - 10.47M -
Short long term debt total 20.77M 21.86M 5.47M 45.77M 38.42M
Other stockholder equity - 1208.42M 1007.56M 766.90M 752.60M
Property plant equipment - - - 1.36M 2.25M
Total current assets 328.65M 383.31M 344.80M 172.81M 237.75M
Long term investments - - - - -
Net tangible assets - - - 96.37M 161.63M
Short term investments 204.26M 271.21M 49.79M 48.93M 32.97M
Net receivables 0.65M 0.61M 0.81M 15.50M 18.35M
Long term debt - - - 29.31M 36.56M
Inventory 1.81M 2.31M 3.91M 2.89M 3.62M
Accounts payable 34.88M 11.72M 6.50M 5.92M 7.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.96M 1.03M 0.86M 0.79M 0.84M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -671.35100M -569.09700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15.12M 5.98M 0.15M 1.51M 0.63M
Deferred long term asset charges - - - - -
Non current assets total 35.34M 35.16M 10.38M 7.55M 25.63M
Capital lease obligations 20.77M 21.86M 4.91M 6.56M 2.64M
Long term debt total - - - 29.31M 36.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 71.70M -219.35500M -3.31500M -15.11500M -32.96500M
Change to liabilities - - - 1.20M 7.54M
Total cashflows from investing activities 68.58M -219.35500M - -17.26500M -33.12100M
Net borrowings -0.10500M -0.10500M - -0.65300M -0.14600M
Total cash from financing activities 173.65M 164.02M 187.07M -0.69000M 216.90M
Change to operating activities - - - 0.07M -0.02800M
Net income -231.96200M -130.87000M -70.79500M -102.25400M -58.41700M
Change in cash 2.12M -181.55900M 185.63M -82.96000M 133.68M
Begin period cash flow 99.85M 281.41M 95.63M 178.74M 45.06M
End period cash flow 101.97M 99.85M 281.26M 95.78M 178.74M
Total cash from operating activities -240.11000M -126.22600M 1.88M -65.00500M -50.09700M
Issuance of capital stock 173.44M 163.31M 226.17M 108.48M 216.82M
Depreciation 2.31M 1.54M 0.46M 2.45M 2.77M
Other cashflows from investing activities 4.83M 5.95M - - -
Dividends paid - - - - -
Change to inventory 0.49M 1.60M -1.55300M -0.76000M 1.35M
Change to account receivables -10.66700M -0.24400M 14.43M -2.66200M -10.60300M
Sale purchase of stock - - -0.16900M -0.29500M -0.15000M
Other cashflows from financing activities -1.38800M 0.81M -1.97000M 7.98M 0.22M
Change to netincome - - - 38.38M 6.66M
Capital expenditures 3.28M 4.05M 3.48M 2.15M 0.16M
Change receivables - - - -2.66200M -10.60300M
Cash flows other operating - - - -1.35700M -0.33100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -82.96000M 133.68M
Change in working capital -33.78100M -27.77300M 58.88M -3.02300M -1.73900M
Stock based compensation 27.87M 36.74M 12.06M 14.18M 7.45M
Other non cash items -4.82800M -5.95300M 1.18M 23.65M 0.63M
Free cash flow -243.39000M -130.27800M -1.60800M -67.15500M -50.25300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EYPT
Eyepoint Pharmaceuticals Inc		 -0.95 7.29% 12.08 - 6.16 37.53 4.11 31.01 11.56
NVO
Novo Nordisk A/S		 0.04 0.09% 43.92 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.40 0.91% 44.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.54 1.24% 450.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.84 0.46% 614.98 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Eyepoint Pharmaceuticals Inc

480 Pleasant Street, Watertown, MA, United States, 02472

Key Executives

Name Title Year Born
Ms. Nancy S. Lurker Pres, CEO & Director 1957
Mr. George O. Elston Chief Financial Officer 1965
Dr. Jay S. Duker M.D. Chief Operating Officer 1959
Mr. David Scott Jones Sr. VP & Chief Commercial Officer 1967
Mr. Said Saim Chief Technology Officer 1958
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Sec. NA
Mr. Michael Pine Chief Corp. Devel. & Strategy Officer 1976
Ms. Jennifer Leonard Chief People Officer & Sr. VP of IT NA
Dr. Dario A. Paggiarino Sr. VP & Chief Medical Officer 1957
Ms. Isabelle Lefebvre Chief Regulatory Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions